The laboratory of Jonathan Kaye, PhD, works on the molecular regulation of cell fate decisions in the immune system, with particular focus on T lymphocytes and innate lymphoid cells.

View NIH Biographical Sketch as a PDF

• Undergraduate: California Institute of Technology, 1976
• Doctorate: Yale University, 1985
• Post Doctorate: University of California, San Diego, 1990

• Cancer Institute (Samuel Oschin Comprehensive Cancer Institute)
• Biomedical Sciences
• Cancer
• Medicine

• Invited Speaker, Cytokines in T Cell and ILC Differentiation Symposium, NIH, Bethesda, MD, 2018
• Chair, NIH, Special Emphasis Panel, NIAID Investigator Initiated Program Project Applications, 2018
• Chair, NIH, Member Conflict Panel, Immune Mechanisms, 2017
• Chair, NIH Investigations on Primary Immunodeficiency Diseases Special Emphasis Panel, 2010-17
• Section Editor: Journal of Immunology, 2009-2013

Click here for a list of peer-reviewed publications.

• Page N, Klimek B, De Roo M, Steinbach K, Soldati H, Lemeille S, Wagner I, Kreutzfeldt M, Di Liberto G, Vincenti I, Lingner T, Salinas G, Brück W, Simons M, Murr R, Kaye J, et al. Expression of the DNA-Binding Factor TOX Promotes the Encephalitogenic Potential of Microbe-Induced Autoreactive CD8+ T Cells. Immunity. 2018 May 15;48(5):937-950.e8. PMCID: PMC6040915
• Harly C, Cam M, Kaye J, Bhandoola A. J Exp Med. 2018 Jan 2;215(1):249-262. PMCID: PMC5748853
• Seehus CR, Kadavallore A, Torre B, Yeckes AR, Wang Y, Tang J, Kaye J. Alternative activation generates IL-10 producing type 2 innate lymphoid cells. Nat Commun. 2017 Dec 1;8(1):1900. PMCID: PMC5711851